1. Home
  2. PGY vs PRAX Comparison

PGY vs PRAX Comparison

Compare PGY & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pagaya Technologies Ltd.

PGY

Pagaya Technologies Ltd.

HOLD

Current Price

$20.91

Market Cap

1.7B

Sector

Finance

ML Signal

HOLD

Logo Praxis Precision Medicines Inc.

PRAX

Praxis Precision Medicines Inc.

N/A

Current Price

$313.87

Market Cap

9.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PGY
PRAX
Founded
2016
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.7B
9.6B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
PGY
PRAX
Price
$20.91
$313.87
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
15
Target Price
$34.50
$572.13
AVG Volume (30 Days)
2.0M
297.8K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
116.43
N/A
EPS
0.77
N/A
Revenue
$1,301,360,000.00
N/A
Revenue This Year
$14.27
N/A
Revenue Next Year
$14.39
$7,758.26
P/E Ratio
$25.94
N/A
Revenue Growth
26.07
N/A
52 Week Low
$10.40
$40.12
52 Week High
$44.99
$392.70

Technical Indicators

Market Signals
Indicator
PGY
PRAX
Relative Strength Index (RSI) 52.43 40.45
Support Level $20.50 $290.53
Resistance Level $23.45 $331.21
Average True Range (ATR) 1.14 14.90
MACD -0.29 -5.02
Stochastic Oscillator 44.98 2.94

Price Performance

Historical Comparison
PGY
PRAX

About PGY Pagaya Technologies Ltd.

Pagaya Technologies Ltd is a product-focused technology company. It uses machine learning, a vast data network, and an AI-driven approach to offer comprehensive consumer credit and residential real estate products for its partners, their customers, and investors. Its suite of products includes Decline Monetization, Dual Look, First Look, Affiliate Optimizer Engine, Direct Marketing Engine, and FastPass, providing lenders with an AI-powered credit and acquisition ecosystem that helps them approve more borrowers, capture more demand, and grow without adding risk. Geographically, the company generates maximum revenue from its business in the United States.

About PRAX Praxis Precision Medicines Inc.

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Share on Social Networks: